维莫非尼治疗伴脑转移的转移性黑色素瘤患者:一项开放标签、单臂、2期、多中心研究
这项2期多中心开放标签单臂研究纳入146例BRAFV600突变伴脑转移的黑色素瘤患者,分队列1(90例,脑转移未经治疗)和队列2(56例,脑转移经治),接受维莫非尼960 mg每日两次治疗。队列1颅内独立评审委员会评估的最佳总缓解率为18%(2例完全缓解,14例部分缓解),结论认为维莫非尼对黑色素瘤脑转移有临床意义的缓解率且耐受良好。
要点
- 队列1颅内独立评审委员会评估的最佳总缓解率为18%(2例完全缓解,14例部分缓解)。
- 队列1颅外最佳总缓解率为33%,队列2为23%。
- 3/4级不良事件发生率队列1为66%(59例),队列2为64%(36例),无显著中枢神经系统毒性。
核心结论
- 研究显示维莫非尼对黑色素瘤脑转移具有临床意义的缓解率,耐受良好且无显著中枢神经系统毒性。
研究设计与样本
- 开放标签、单臂、2期、多中心研究。
- 共治疗146例BRAFV600突变伴脑转移的黑色素瘤患者,队列1(脑转移未经治疗)90例,队列2(脑转移经治疗)56例,62%为男性。
- 患者接受维莫非尼960 mg每日两次,直至疾病进展或不耐受。
- 主要终点为队列1颅内最佳总缓解率,采用改良RECIST 1.1标准以≥0.5 cm病灶评估。
主要发现
- 队列1脑转移诊断至入组的中位时间(范围)为1.0(0-9)个月,队列2为4.2(1-68)个月。
- 队列1中位治疗持续时间(范围)为4.1(0.3-34.5)个月,队列2为4.1(0.2-27.6)个月。
- 队列1颅内最佳总缓解率(独立评审委员会评估)为18%(2例完全缓解,14例部分缓解)。
- 颅外最佳总缓解率(独立评审委员会评估)队列1为33%,队列2为23%。
- 队列1中位无进展生存期(仅脑部,研究者评估)为3.7个月(范围0.03-33.4;IQR 1.9-5.6),队列2为4.0个月(范围0.3-27.4;IQR 2.2-7.4);队列1中位总生存期为8.9个月(范围0.6-34.5;IQR 4.9-17.0),队列2为9.6个月(范围0.7-34.3;IQR 4.5-18.4)。
关键数值与推荐
- 队列1颅内最佳总缓解率(独立评审委员会评估)为18%(2例完全缓解,14例部分缓解)。
- 颅外最佳总缓解率(独立评审委员会评估)队列1为33%,队列2为23%。
- 3/4级不良事件发生率队列1为66%(59例),队列2为64%(36例)。
- 总体84%的患者在研究期间死亡(队列1为86%,队列2为80%),主要死于疾病进展。
临床怎么用
- 维莫非尼960 mg每日两次可用于BRAFV600突变伴脑转移的黑色素瘤患者,队列1(脑转移未经治疗)及队列2(脑转移经治疗)均纳入。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM. METHODS: Patients with BRAFV600 mutated melanoma with BM were enrolled into cohort 1 (previously untreated BM) and cohort 2 (previously treated BM) and received vemurafenib (960 mg BID) until disease progression (PD) or intolerance. Primary endpoint was best overall response rate (BORR) in the brain in cohort 1 that was evaluated using modified RECIST 1.1 criteria using lesions ≥0.5 cm to assess response. RESULTS: 146 patients were treated (cohort 1 n = 90; cohort 2 n = 56), 62% of whom were male. Median (range) time since diagnosis of BM: 1.0 (0-9) month in cohort 1 and 4.2 (1-68) months in cohort 2. Median duration of treatment was 4.1 months (range 0.3-34.5) in cohort 1 and 4.1 months (range 0.2-27.6) in cohort 2. Intracranial BORR in cohort 1 by an independent review committee (IRC) was 18% (2 CRs, 14 PRs). Extracranial BORR by IRC was 33% in cohort 1 and 23% in cohort 2. Median PFS (brain only, investigator-assessed) was 3.7 months (range 0.03-33.4; IQR 1.9-5.6) in cohort 1 and 4.0 months (range 0.3-27.4; IQR 2.2-7.4) in cohort 2. Median OS was 8.9 months (range 0.6-34.5; IQR 4.9-17.0) in cohort 1 and 9.6 months (range 0.7-34.3; IQR 4.5-18.4) in cohort 2. Adverse events (AEs) were similar in type, grade and frequency to other studies of single-agent vemurafenib. Grade 3/4 AEs occurred in 59 (66%) patients in cohort 1 and 36 (64%) in cohort 2. Overall, 84% of patients died during the study (86% in cohort 1 and 80% in cohort 2), mainly due to disease progression. CONCLUSIONS: The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity.
引用
- McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017. PMID: 27993793. doi:10.1093/annonc/mdw641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。